Results for high risk patients (aged 65 years and requiring an ICU stay) using all available isolates | Ceftolozane/tazobactam + metronidazole | Piperacillin/tazobactam | Incremental Ceftolozane/tazobactam + metronidazole - Piperacillin/tazobactam |
---|---|---|---|
Total costs per patient | $41,838 | $42,501 | -$662 |
Total QALYs (discounted) per patient | 11.38 | 11.24 | 0.14 |
Incremental Cost Effectiveness Ratio (Cost per discounted QALY saved) | – | – | Dominant |
Results for high risk patients (aged 65 years and requiring an ICU stay) using nosocomial isolates | Ceftolozane/tazobactam + metronidazole | Piperacillin/tazobactam | Incremental Ceftolozane/tazobactam + metronidazole - Piperacillin/tazobactam |
Total costs per patient | $42,979 | $44,403 | -$1424 |
Total QALYs (discounted) per patient | 11.75 | 11.53 | 0.22 |
Incremental Cost Effectiveness Ratio (Cost per discounted QALY saved) | – | – | Dominant |
Results when lifetime health care expenditure for health survivors is excluded | Ceftolozane/tazobactam + metronidazole | Piperacillin/tazobactam | Incremental Ceftolozane/tazobactam + metronidazole - Piperacillin/tazobactam |
Total costs per patient | $16,286 | $17,265 | -$978 |
Total QALYs (discounted) per patient | 12.85 | 12.70 | 0.15 |
Incremental Cost Effectiveness Ratio (Cost per discounted QALY saved) | Â | Â | Dominant |